Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

PTC Therapeutics, Inc. PTCT

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
63.23
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 6 6 5 16 8 5 4 3 6 5 4 1
Insider Ownership
2.63%

Capital & Financial Ratios

Market Cap
5,680.00
Revenue
1,008.75
Net Income
(38.38)
Free Cash Flow
(300.25)
Net Debt
683.32
Current Ratio
3.39
Debt/Equity
(17.61)
P/E ratio
0.00
P/S ratio
5.38
P/B ratio
0.00
Past 5Y EPS Growth
(2.04%)
This Y EPS Growth
(83.67%)
Next Y EPS Growth
113.64%
Next 5Y EPS Growth
(14.21%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 876.74 1,139.70 1,945.37 2,229.08
Receivables 160.82 158.55 181.62 239.04
Inventory 30.58 23.19 79.65 91.35
Other — — — —
1,218.63 1,365.53 2,273.95 2,617.36
2023 2024 2025 Q'26
Payables 391.98 304.29 381.27 382.25
ST’ Debt 194.31 257.82 569.63 369.67
Other — — — —
603.10 580.98 968.43 771.07
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 272.55 360.52 — —
—
’25 1,176.10 178.88 211.01 164.68
1,730.66
’24 210.12 186.70 196.79 213.17
806.78
’23 220.38 213.81 196.58 307.06
937.82
’22 148.74 165.53 217.13 167.41
698.80
’21 117.94 116.68 138.74 165.23
538.59
’20 68.26 75.24 118.40 118.86
380.77
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (59.04) 129.11 — —
—
’25 870.10 (58.33) (66.30) (34.27)
711.20
’24 70.76 (71.45) (76.99) (30.00)
(107.69)
’23 (29.49) (14.12) (14.52) (100.29)
(158.42)
’22 (97.40) (55.24) (38.04) (165.96)
(356.65)
’21 (100.16) (31.14) (51.19) (68.84)
(251.33)
’20 (81.55) (74.81) 26.66 (64.37)
(194.07)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (60.39) 121.97 — —
—
’25 867.64 (62.33) (322.50) (36.65)
702.41
’24 6.41 (36.04) (142.51) (36.50)
(153.88)
’23 (73.16) (33.40) (90.16) (128.75)
(279.04)
’22 (178.85) (73.23) (64.07) (192.96)
(509.11)
’21 (120.02) (39.12) (98.84) (92.88)
(336.66)
’20 (99.01) (76.97) (2.27) (83.23)
(250.05)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.03) 0.92 — —
—
’25 10.04 (0.83) 0.20 (1.67)
7.78
’24 (1.20) (1.29) (1.39) (0.85)
(4.73)
’23 (1.88) (2.66) (1.76) (2.06)
(8.37)
’22 (1.78) (2.13) (1.53) (2.35)
(7.79)
’21 (1.83) (1.68) (1.89) (2.03)
(7.43)
’20 (1.81) (2.78) (1.03) (1.08)
(6.64)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.7
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.01 17.53 23.58 35.95 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55.58 59.84 54.16 87.50 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,410 995 939 991 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.50 0.94 0.86 1.75 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 698.80 937.82 806.78 1,730.66 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 93.61% 93.02% 92.89% 97.28% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (587.49) (696.11) (363.12) 696.62 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (84.07%) (74.23%) (45.01%) 40.25% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (559.02) (626.60) (363.29) 682.64 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 165.83 454.06 223.88 22.01 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.74 12.53 10.50 21.76 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.79) (8.37) (4.73) 8.58 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.97) (2.12) (1.40) 8.94 ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.13) (1.61) (0.60) (0.11) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.10) (3.73) (2.00) 8.83 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.84) (10.94) (14.29) (2.58) ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 71.73 74.84 76.85 79.53 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 8.64 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.92 2.24 4.30 3.49 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.26 3.56 5.84 3.87 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.22) (10.25) (20.35) 15.10 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (356.65) (158.42) (107.69) 711.20 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (152.46) (120.62) (46.19) (8.79) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (509.11) (279.04) (153.88) 702.41 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 287.55 615.53 784.55 1,305.52 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,348.28 2,115.49 2,382.76 2,598.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 937.58 1,238.76 1,243.07 652.63 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (347.09) (818.55) (1,098.07) (205.31) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (30.68%) (34.80%) (20.18%) 29.66% — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.36%) (65.37%) (130.42%) 121.13% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 323.46% 107.51% 37.91% (104.75%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

PTC Therapeutics (PTCT), a biopharma player specializing in rare genetic disorders like DMD and PKU, has delivered explosive revenue growth—from $83 million in 2016 to a 2023 peak of $938 million—powered by orphan drugs like Translarna, Emflaza, and the new Daybue launch. Despite a 2024 dip to $807 million due to commercialization snags, analysts forecast a stunning 129% surge to $1.85 billion in 2025, flipping the company to $796 million profit and positive EPS of $9.64. Shares trade at levels suggesting 27% upside to consensus targets (79% to the high), hinting at undervaluation amid resilient 93% gross margins and operational efficiencies.

Yet challenges loom large: chronic losses have eroded equity to negative $1.1 billion, net debt hit $1.24 billion, and cash burn persists, fueling leverage risks and covenant worries tied to ongoing FDA battles over Translarna. Heavy insider selling—$45.9 million with zero buys—adds caution, even as revenue per employee and European dominance shine.

This sets up a high-stakes inflection: Daybue’s ramp-up, potential U.S. approvals, and pipeline catalysts could drive 20-30% CAGR, slashing debt and unlocking multiples. But regulatory rebuffs or execution slips could exacerbate dilution risks—making PTCT a volatile watchlist gem for risk-tolerant investors eyeing the rebound.

Read full commentary →

PTC Therapeutics, Inc. (PTCT) Latest News

News by impact score

Fine-tune

20 Sep

3 , 2:14 AM
PTC Therapeutics (PTCT) stock could be 36% undervalued due to progress in its drug pipeline. Pipeline progress supports a higher valuation for PTCT shares.

24 Aug

4 , 8:00 AM
PTC Therapeutics announces new Sephience (sepiapterin) data showing sustained metabolic control, diet liberalization benefits, broad patient applicability and consistent favorable safety profile. Positive pivotal data on lead asset sepiapterin strengthens regulatory and commercial outlook for PTCT.

3 , 12:51 PM
Pipeline promise at PTC Therapeutics contrasts with revenue risks, prompting questions over KROS stock purchase viability. Pipeline and revenue factors create moderate influence on PTCT trajectory without guaranteed fundamental shifts.

16 Aug

4 www.marketbeat.com, 11:01 AM
PTC Therapeutics pursues Fabry gene therapy assets in a $111M bankruptcy auction deal. Acquisition expands PTC's gene therapy pipeline in rare diseases with major strategic value.

13 Aug

4 www.biopharmadive.com, 7:10 AM
PTC Therapeutics acquires rights to Sangamo's ST-920 gene therapy program for Fabry disease, expanding its rare disease pipeline through a licensing deal. Licensing deal adds clinical-stage gene therapy asset to PTC pipeline with potential to drive future revenue in rare diseases.

12 Aug

4 , 4:01 PM
PTC Therapeutics acquires BLA-stage ST-920 Fabry disease program to expand rare disease portfolio. Late-stage program acquisition bolsters PTC's rare disease pipeline and long-term growth outlook.

31 Jul

4 transcript , 1:04 AM
PTC Therapeutics reported record Q2 2026 revenue and raised guidance in its earnings call. Record revenue and raised guidance indicate strong results likely to lift stock trajectory and sentiment.

3 transcript www.marketbeat.com, 9:02 PM
PTC Therapeutics Q2 earnings call highlighted financial results, operational updates, and future guidance for the company. Q2 earnings and guidance directly influence near-term stock movement and investor outlook.

3 , 9:30 AM
PTC Therapeutics reported Q2 earnings with key financial metrics compared to analyst estimates. Q2 earnings metrics versus estimates deliver routine financial updates that may moderately sway near-term investor views.

30 Jul

3 , 4:01 PM
PTC Therapeutics reported second quarter 2026 financial results and issued a corporate update. Quarterly results and updates affect near-term investor views and valuation but rarely shift long-term trajectory.

11 Jul

3 , 4:16 AM
PTC Therapeutics stock may be fully priced following rare disease data release. Rare disease data prompts full valuation assessment capping near-term upside.

2 Jul

3 , 9:34 AM
CPRX's Agamree shows positive Phase I data with potential applications beyond Duchenne Muscular Dystrophy. Positive competitor data on Agamree may modestly increase rivalry for PTCT products in DMD and adjacent indications.

17 Jun

4 , 3:33 PM
PTC Therapeutics stock surges 81% after receiving surprise positive FDA news. FDA regulatory news triggers 81% stock surge and signals major near-term catalyst for PTC Therapeutics.

7 Jun

4 Simply Wall St., 8:06 AM
PTC Therapeutics faces shifting company narrative and valuations driven by revised Sephience assumptions that are prompting new investor models. Revised Sephience assumptions are prompting new valuations that can materially alter PTC Therapeutics' market trajectory.

22 May

3 Zacks, 11:03 AM
KROS outlines Rinvatercept development plans for DMD and ALS with potential 2026 milestones that may affect PTCT's positioning in neuromuscular disease markets. Competitor progress on Rinvatercept in DMD and ALS indications creates moderate pressure on PTCT's existing therapies and pipeline outlook.

3 Zacks, 11:03 AM
Keros Therapeutics releases Rinvatercept stock guide focused on DMD and ALS programs with key milestones projected for 2026. Rinvatercept progress introduces competitive pressure in DMD that may affect PTCT positioning and sentiment.

8 May

4 app.moby.co, 8:30 AM
PTC Therapeutics, Inc. (PTCT) issued Q1 2026 earnings call summary covering financial results, pipeline updates, and forward guidance. Quarterly earnings summaries often drive significant shifts in investor sentiment and stock trajectory based on revenue, guidance, and operational highlights.

3 www.marketbeat.com, 5:07 PM
PTC Therapeutics Q1 earnings call highlights key financial results, including revenue growth from Translarna and Evrysdi collaborations, pipeline progress in DMD, AADC deficiency, and oncology programs, reaffirmed 2024 guidance, and updates on regulatory filings. Q1 earnings highlights cover financials and pipeline affecting performance but balanced by ongoing challenges.

7 May

4 Zacks, 6:30 PM
PTC Therapeutics (PTCT) Q1 earnings compared to analyst estimates, with analysis of key metrics including revenue, EPS, and operational highlights. Q1 earnings comparison to estimates directly impacts financial performance, investor sentiment, and stock trajectory.

4 PR Newswire, 4:01 PM
PTC Therapeutics provided a corporate update and reported first quarter 2026 financial results. Quarterly financial results and corporate updates significantly affect investor sentiment, stock price, and future trajectory.

3 Zacks, 5:55 PM
PTC Therapeutics (PTCT) reported a first-quarter net loss but surpassed Wall Street revenue estimates. Quarterly loss despite revenue beat impacts financial performance and investor sentiment moderately.

5 May

4 Simply Wall St., 9:18 AM
PTC Therapeutics (PTCT) valuation reassessed upward after encouraging new Huntington’s Disease data from vatiquinone trial, boosting analyst price targets and highlighting pipeline potential amid rising shares. Encouraging Huntington’s Disease trial data significantly strengthens PTCT's rare disease pipeline and investor sentiment.

4 May

3 , 9:13 PM
PTC Therapeutics (PTCT) investment narrative shifts due to Sephience developments and intensifying franchise pressures. Sephience and franchise pressures moderately influence PTCT's financial performance and competitive positioning.

2 May

4 Insider Monkey, 1:51 PM
PTC Therapeutics announced positive results from its Huntington’s Disease clinical trial, demonstrating efficacy in key endpoints and supporting further development. Positive Huntington’s Disease trial results represent a major pipeline advancement that could drive regulatory progress, partnerships, and significant stock appreciation.

30 Apr

4 Simply Wall St., 6:05 PM
PTC Therapeutics (PTCT) shares dropped 5.1% after release of new Votoplam data for Huntington’s disease and a Novartis milestone payment. Disappointing Votoplam Huntington’s data triggered a 5.1% stock decline, impacting pipeline progress and investor confidence despite Novartis milestone.

29 Apr

4 www.marketbeat.com, 4:31 AM
PTC Therapeutics announced 24-month data for Votoplam showing dose-linked signals of slowing Huntington’s disease progression. Positive long-term clinical data for Votoplam in Huntington’s could significantly enhance PTCT’s pipeline, drive stock gains, and improve regulatory prospects.

28 Apr

4 PR Newswire, 4:05 PM
PTC Therapeutics announced positive topline results from the Month 24 interim analysis of the PIVOT-HD extension study for Votoplam, demonstrating sustained clinical benefit in Huntington's disease patients. Positive long-term interim data from PIVOT-HD extension bolsters Votoplam's approval prospects and could significantly lift PTCT's valuation.

4 PR Newswire, 9:28 AM
PTC Therapeutics to report results from PIVOT-HD long-term extension study. Long-term extension results from PIVOT-HD could significantly advance PTCT's Huntington's disease program and drive substantial market reaction.

20 Apr

4 , 11:41 AM
KROS 2026 Watchlist spotlights PTC Therapeutics (PTCT) with three catalysts poised to reset investor sentiment. Three catalysts could significantly alter PTCT's trajectory and investor sentiment.

4 , 11:29 AM
KROS rinvatercept prepares for Phase II trials in Duchenne muscular dystrophy, highlighting key details on mechanism, prior data, competitive landscape, and potential impact for PTC Therapeutics ahead of trial start. Upcoming Phase II trial initiation for DMD candidate represents major pipeline advancement with potential to significantly enhance PTCT's competitive position and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us